AstraZeneca explores options after anselamimab fails Phase 3, while Imfinzi and Tremfya receive label expansions

AstraZeneca announced that its experimental monoclonal antibody anselamimab failed to meet the primary endpoint in two Phase 3 trials for a specific patient group.

The company said it will explore alternative development paths for the molecule, such as different indications or combination approaches.

At the same time, AstraZeneca reported regulatory label expansions for its cancer immunotherapy Imfinzi and its psoriasis treatment Tremfya, extending their approved uses.

These updates highlight both the setback of a late-stage trial failure and the continued growth of the company's existing product portfolio.